Mumbai-based Cipla reported a 12.4% fall in net profit for the fourth quarter of FY2021-22 to Rs.362 crore due to the impact of impairments. Quarterly sales rose 14.2% to Rs 5,260 crore and Ebitda fell 4.2% to Rs 763 crore.

For the full year, Cipla recorded a 4.7% increase in net profit to Rs.2,517 crore, while revenue and Ebitda rose 13.6% and 6.4% to Rs.21,763 crore and Rs.4578 million, respectively.

      

Excluding the impact of Covid-19 one-off inventory and other charges of Rs. 200 crore in Q4, the Adjusted EBITDA Margin for FYQ4 is 22 18% (Ebitda Rs. 960 million) and for the full year 22% (Ebitda Rs. 4,775 crore). .

Cipla's business in India saw strong year-over-year growth of 21% in branded prescription, commercial generic and consumer health and 15% year-on-year adjusted for the Covid-19 portfolio. The U.S. business reported $160 million in revenue and 17% year-over-year growth, driven by traction in respiratory and peptide assets.

Umang Vohra, MD and Global CEO of Cipla said seasonality affects the overall business mix. “Our One India business continued double digit growth during the quarter. We passed the $1 billion milestone in our nationally branded prescription business, driven by continued growth of our acute and chronic product portfolio. »

Vohra further added that the established respiratory franchise and the contribution of peptides have boosted the US run-rate to $160 million.

"Taking into account Covid-related and other one-off costs, our core operating profitability continues to be strongly supported by the strength of our business fundamentals. We continue to respond to the challenging entry cost environment through cost optimization and mixed management." "We are pleased with the complex launches in the second half of FY23, which will continue to strengthen overall business performance and profitability," he stated.

Revenue from the company's bulk drug (API) business declined 38.7% due to customer inventories and a one-time profit share on API delivery.


Also Read: Highest Paying Jobs in India in 2022